

1626  
TFW

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		Docket Number: <b>01662/50302</b>	
Application Number 09/714,351	Filing Date November 16, 2000	Examiner L. Stockton	Art Unit 1626
Invention Title <b>Polymorphic Form of Atorvastatin Calcium</b>		Inventors Ayalon, et al.	

Address to:  
Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. box 1450, Alexandria, VA 22313-1450

on  
Date: 2/21/06

Signature: Agnes Xu  
Agnes Xu


1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references to the attention of the Examiner. The references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
3. A copy of each non-U.S. patent, non-U.S. published application, unpublished U.S. application, non-patent publication, or other information listed on the PTO form 1449 is enclosed.
4. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a final action, Notice of Allowance, or any action that otherwise closes prosecution.
5. Please debit Deposit Account No. **11-0600** in the amount of \$180.00 in payment of the fee under 37 CFR §1.17(p) to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached. 37 CFR §1.97(c)(2).

Dated: **FEBRUARY 16, 2006**

By: Joseph A. Coppola  
Joseph A. Coppola (Reg. No. 38,413)

02/28/2006 SLUANG1 00000006 110600 09714351  
01 FC:1806 180.00 DA

KENYON & KENYON LLP  
One Broadway  
New York, N.Y. 10004  
(212) 425-7200 (telephone)  
(212) 425-5288 (facsimile)  
**CUSTOMER NO. 26646**



**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
PTO-1449**

ATTY. DOCKET NO.  
1662/50302

SERIAL NO.  
09/714,351

APPLICANT  
Ayalon, et al.

FILING DATE  
November 16, 2000

GROUP  
1626

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
	5,003,080	March 26, 1991	Butler et al.			
	5,298,627	March 29, 1994	Butler et al.			
	6,605,729	August 12, 2003	Byrn et al.			
	5,686,104	May 20, 1994	Mills et al.			
	6,605,636	November 5, 2001	Aronhime et al.			
	6,605,728	June 14, 2002	O'Connell et al.			
	6,528,661	March 4, 2003	Niddam et al.			

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 02/059087	August 1, 2002	PCT				
	WO 02/083637	October 24, 2002	PCT				
	WO 02/083638	October 24, 2002	PCT				
	WO 03/018547	March 6, 2003	PCT				
	WO 03/070702	August 28, 2003	PCT				
	WO 97/03960	July 16, 1996	PCT				
	WO 02/057228	January 17, 2001	PCT				

**OTHER DOCUMENTS**

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Bang-Chi Chen et al., "Synthesis of Deuterium-Labeled Atorvastatin and its Metabolites for Use as Internal Standards in a LC/MS/MS Method Developed for Quantitation of the Drug and its Metabolites in Human Serum," Journal of Labelled Compounds and Radiopharmaceuticals 43 (2000) pp. 261-270*
	K.L. Baumann et al., "The Convergent Synthesis of CI-981, an Optically Active, Highly Potent, Tissue Selective Inhibitor of HMG-CoA Reductase," Tetrahedron Letters, Vol. 33, No. 17 (1992) pp. 2283-2284
	Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th Ed. ( 1996) pp. 879-881
	Cheronis, Semimicro Experimental Organic Chemistry, pp. 31-49
	Haleblan & Crone, 1969. J. Pharm. Sci.58:911-929
	G. Michael Wall, "Pharmaceutical Applications of Drug Crystal Studies", Pharmaceutical Manufacturing (Feb 1986) pp. 33-42
	U.S. Pharmacopia #23, p. 1843, 941 X-Ray Diffraction
	2004/0054193, Published US Patent Application, March 18, 2004, Byrn et. al.
	2004/0077708, Published US Patent Application, April 22, 2004, Grahek et. al.
	2003/0114686, Published US Patent Application, June 19, 2003, Van der Schaaf et. al.
	2004/0106670, Published US Patent Application, June 3, 2004, Blatter et. al.
	2003/0216584, Published US Patent Application, November 20, 2003, Aronhime et. al.
	10/994,142, Pending US Patent Application, November 19, 2004, Aronhime et. al.
	2002/0115709, Published US Patent Application, August 22, 2002, Aronhime et. al.
	2003/212279, Published US Patent Application, November 13, 2003, Tessler et. al.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
PTO-1449**

ATTY. DOCKET NO.  
1662/50302

SERIAL NO.  
09/714,351

APPLICANT  
Ayalon, et al.

FILING DATE  
November 16, 2000

GROUP  
1626

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
	US 4,137,322 A	30 January 1979	Endo, et al.			
	US 6,476,235	November 2002	Butler, et al.			
	US 6,600,051	July 2003	Tully, Willam			

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 03/016317 A	27 February 2003	PCT				
	WO 00/71116 A	30 November 2000	PCT				
	WO 01/28999 A	26 April 2001	PCT				
	WO 01/42209 A	14 June 2001	PCT				

**OTHER DOCUMENTS**

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	McCrone W.C., "Polymorphism", Physics and Chemistry of the Organic Solid State, vol. 2, 1965, pages 725-767
	Caira M.R., "Crystalline Polymorphism of Organic Compounds" Topics in Current Chemistry, Springer, Berlin, DE, vol. 198, 1998, pages 163-208
	Graul A., et al., "Atorvastatin Calcium" Drugs of the Future, Barcelona, ES, vol. 22, No. 9, 1997, pages 956-968
	Guillory, J.K.: "in Polymorphism in Pharmaceutical Solids (Brittain, H.G., ed.)", 1999, Marcel Dekker, Inc., New York, Basel, pages 183-226
	Hancock B.C., et al., "Characteristics and Significance of the Amorphous State in Pharmaceutical Systems", Journal of Pharmaceutical Sciences, American Pharmaceutical Association, Washington, U.S., vol. 86, no. 1, January 1997, pages 1-12
	Concise Encyclopedia Chem. (1993), Walter deGruyter, Berlin, NY.
	2004/0220255, Published US Patent Application, Van Der Schaaf, et al., November, 2004
	2004/0242899, Published US Patent Application, Reddy, et al., December, 2004
	2004/0209306, Published US Patent Application, Jegorov, et al., September 2005
	2002/0099224, Published US Patent Application, Niddam, et al., July 25, 2002

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	